Related by context. All words. (Click for frequent words.) 77 clinicaltrials.gov 75 www.ClinicalTrials.gov 74 ClinicalTrials.gov 74 http:/www.clinicaltrials.gov 73 number NCT# ClinicalTrials.gov 71 NCT# 69 www.clinicaltrials.gov 68 identifier NCT# 67 Current Controlled Trials 67 ID NCT# 67 Triapine R 66 clinicaltrials 66 Tesmilifene 65 confirmatory Phase IIIb 65 http:/www.clinicaltrials.gov/ 65 www.pranabio.com 65 aurora kinase 65 LUMINATE 65 prospective multicentre 65 ThermoDox ® clinical 65 BR.# 64 www.cellceutix.com 64 http:/www.hematology.org 64 ClinicalTrials.gov Identifier NCT# 64 CHAMPION PCI 64 cancer.gov 64 www.niddk.nih.gov 64 BRIM3 64 www.novartis.com 64 www.cancer.gov 64 Phase Ib II 64 Enzastaurin 64 acyclovir Lauriad R 64 GATTEX ® 63 www.asco.org 63 clevidipine 63 Anticancer Programs section 63 Trandolapril 63 www.alexionpharma.com 63 Full Prescribing Information 63 trastuzumab emtansine T DM1 63 YONDELIS 63 tramiprosate Alzhemed TM 63 Aplidin R 63 MAGE A3 ASCI 63 ZOLINZA 63 www.accentia.net 63 Phase 1a clinical 63 ToGA 63 atherothrombosis 63 Cardiotoxicity 63 clinical pharmacology studies 63 phase IIIb 62 BRIM2 62 LibiGel ® 62 please visit www.advaxis.com 62 Phase IIIb clinical 62 TASKi2 62 lorcaserin Phase 62 FOLOTYN ® 62 www.celsion.com 62 alpha antagonist 62 novel VDA molecule 62 Phase #b/#a clinical 62 EDEMA3 62 Acute Decompensated Heart Failure 62 Phase IIIb 62 Phase III randomized controlled 62 PI3K/Akt pathway inhibitor 62 clinico pathological 62 Quinamed 62 ZACTIMA 62 CIMZIA TM certolizumab pegol 62 galiximab 62 florbetaben 62 mertansine 62 Virulizin ® 62 www.aacr.org 62 http:/www.kaloramainformation.com/redirect.asp?prMinister Jayaram Jayalalitha 62 Zemplar Capsules 62 www.hematology.org 62 multicenter Phase II 62 genomic biomarker 62 lumiliximab 62 relapsed MM 61 DEB# 61 dbGaP 61 biliary tract cancer 61 TLR antagonists 61 alvespimycin 61 PROactive study 61 Cimzia ® certolizumab pegol 61 ISRCTN# 61 ENESTnd 61 CIMZIA ™ 61 www.gene.com 61 please visit http:/www.sunesis.com 61 LEVADEX ™ 61 Diabetic Neuropathy 61 HORIZONS AMI 61 STRIDE PD 61 www.gsk.com 61 NSABP B 61 programs visit http:/www.bionovo.com 61 R roscovitine 61 www.vivus.com 61 Solorel 61 midstage clinical 61 Phase Ib clinical 61 sorafenib tablets 61 ANCHOR trial 61 treatment naive genotype 61 AIM HIGH 61 SUTENT ® 61 Raptiva ® 61 www.bioalliancepharma.com 61 Raptiva R 61 www.avigen.com 61 GW# [003] 61 www.syntapharma.com 61 visit www.novabaypharma.com 61 Urocortin 2 61 OVATURE 61 Tanespimycin 61 nih.gov 61 cro.com 61 Cellceutix web 61 Pharmaprojects 61 crizotinib PF # 61 CYT# potent vascular disrupting 61 Archexin 61 multicenter Phase III 61 desvenlafaxine 61 Oral Insulin Capsule 61 SNT MC# 61 AVOREN 61 EGS# 61 www.consumerlab.com 61 multicenter multinational 61 Natalizumab 61 http:/www.gene.com/ 61 Product Monograph 61 Arranon 61 NABTT 61 http:/www.vivus.com 61 budesonide foam 60 www.xoma.com 60 cobiprostone 60 PANVAC VF 60 www.sanofi aventis.us 60 RhuDex 60 phase IIb trial 60 elacytarabine 60 dose escalation phase 60 Renal Cell Carcinoma RCC 60 Targretin capsules 60 PREOS R 60 phase IIa clinical 60 TAXUS ARRIVE 60 vidofludimus 60 Medwatch 60 www.soliris.net 60 HuMax EGFr 60 Aryplase 60 www.vioquestpharm.com 60 PDX pralatrexate 60 Systemic Lupus Erythematosus SLE 60 Phase #/#a 60 ASTEROID 60 visit www.lupus.org 60 NCT# ClinicalTrials.gov 60 EXPLORE Xa 60 tanespimycin 60 molecular biomarker 60 www.roche 60 BCIRG 60 rALLy clinical trial 60 randomized controlled multicenter 60 www.telik.com 60 Phase III placebo controlled 60 REMINYL ® 60 trastuzumab DM1 T DM1 60 omacetaxine mepesuccinate 60 Cimzia TM 60 www.boehringer ingelheim.com 60 AA Amyloidosis 60 multicentre prospective 60 www.centerwatch.com 60 humanised antibody 60 Glucosamine Chondroitin Arthritis 60 DCVax R 60 icatibant 60 Temsirolimus 60 randomized Phase IIb 60 Nexavar prescribing 60 Pivotal Phase III 60 http:/www.curagen.com 60 ASCO abstract 60 uricase 60 blinded randomized placebo controlled 60 Dacogen decitabine 60 OncoVex 60 STEP BD 60 See CLINICAL PHARMACOLOGY 60 www.pbmi.com 60 http:/www.atherogenics.com 60 Dacogen injection 60 assessing T DM1 60 phase IIb study 60 UPLYSO 60 PROSTVAC ® 60 Saxagliptin 60 OVATURE trial 60 Phase III ThermoDox 60 visit http:/www.clinicaltrials.gov/ 60 GLOBOCAN 60 MERLIN TIMI 60 HCV RESPOND 2 60 Proellex TM 60 prospective observational cohort 60 sunitinib malate 60 PROSTVAC TM 60 fosbretabulin 60 observational cohort study 60 rALLy trial 60 IL# PE#QQR 60 brivanib 60 Pyridorin 60 Phase IIIb study 60 Phase IIb III 60 CALGB 60 HCV polymerase 60 Olmesartan 60 http:/www.diabetes.org 60 HeFH 60 SYN# 60 thorough QT 60 med.com 59 Evoltra ® 59 cell.com 59 www.gpc biotech.com 59 HER2 overexpression 59 Initiates Phase III 59 RE LY trial 59 www.thelancet.com 59 ENDEAVOR IV 59 Diamyd r 59 Chronic Heart Failure 59 CATIE AD 59 GetGoal Phase III 59 Trastuzumab DM1 59 Aplidin 59 placebo controlled Phase III 59 phase IIb clinical 59 SAR# [004] 59 Serious Adverse Events 59 SmPC 59 www.cardiome.com 59 interferon gamma 1b 59 PRIALT 59 briakinumab 59 Randomized Phase II 59 Phase #b/#a 59 Squalamine 59 tumor histology 59 oral FTY# 59 recurrent metastatic ovarian cancer 59 www.rxipharma.com 59 ongoing Phase IIIb 59 RAPTIVA 59 CaPSURE 59 ThermoDox R 59 Safinamide 59 BOLDER II 59 HCV SPRINT 59 NCCTG 59 PsA 59 Chronic Lymphocytic Leukemia CLL 59 Removab 59 HoFH 59 IMiDs ® compound 59 NIH registry www.clinicaltrials.gov 59 PrevOnco 59 INS# [001] 59 metastatic neuroendocrine tumors 59 XYOTAX TM 59 Edge STudy 59 NATRECOR R 59 Clinical Antipsychotic Trials 59 trastuzumab Herceptin ® 59 Hepatotoxicity 59 Pertuzumab 59 sargramostim 59 Hedgehog Pathway Inhibitor 59 JAK2 inhibitor 59 genotypic resistance 59 prospective nonrandomized 59 pivotal bioequivalence 59 forodesine 59 Cloretazine 59 Phase III HEAT 59 http:/www.gpc-biotech.com 59 SYMMETRY trial 59 www.orexigen.com 59 prasterone 59 www.micromet.com 59 Maven Semantic 59 arzoxifene 59 pharma.com 59 tubulin inhibitor 59 Randomized Double blind 59 www.oncolyticsbiotech.com 59 LEUKINE 59 www.adeonapharma.com 59 eosinophilic asthma 59 ADAGIO study 59 iii GTx 59 hypereosinophilic syndrome 59 evaluating mipomersen 59 www.micromet inc.com 59 MoxDuo IR 59 LUX Lung 59 CombAT 59 VITAL Trial 59 DIRECT Trial 59 INSPIRE Trial Phase III 59 Matrix Phase 2b 59 Phase III Pivotal 59 Specifid 59 tarenflurbil 59 Actimmune ® 59 OvaRex ® MAb 59 www.paintrials.com 59 www.quintiles.com 59 www.allos.com 59 kidney urologic 59 topical NSAIDs 59 heFH 59 controlled multicenter Phase 59 www.vicortech.com 59 r hGH 59 BEXXAR Therapeutic Regimen 59 Androxal TM 59 neratinib 59 mild hepatic impairment 59 Brentuximab Vedotin SGN 59 PROMACTA CARES 59 Prescribing Information 59 Recurrent Glioblastoma 59 refractory chronic lymphocytic 59 AZILECT R 59 SABCS 59 budesonide MMX Phase III 59 HDL Selective Delipidation 59 CALGB # [002] 59 riociguat 59 recurrent herpes labialis 59 MEND CABG 59 Velcade bortezomib 59 XL# SAR# 59 multicentre randomized 59 Tumor Response 59 Phase III ADT 59 Virulizin R 59 Severe Sepsis 59 recurrent metastatic 59 NOX E# 59 indications contraindications 59 non nucleoside HCV 59 Phase III Clinical Trials 59 www.stemcellsinc.com 59 www.ingenuity.com 59 midstage trials 59 placebo controlled clinical 59 ACCORD Lipid 59 Phase IIb clinical trials 59 Pre RELAX AHF 59 JAK Inhibitor 59 Package Insert 58 Phase Ib IIa 58 PEARL SC 58 Sipuleucel T 58 GERD migraine headaches 58 ACUITY trial 58 Panzem NCD 58 Glypromate 58 Phase IIIB IV 58 LibiGel testosterone gel 58 Elitek 58 Medullary Thyroid Cancer 58 Phase IIA 58 selective estrogen receptor modulator 58 ASCO GI 58 CCR5 receptor antagonist 58 ganetespib 58 PROactive Study 58 REVEAL Registry 58 Epirubicin 58 brivaracetam 58 www.osteologix.com 58 including eniluracil ADH 58 Cancer Immunology Immunotherapy 58 APEX AMI trial 58 Emerging Therapies 58 Hepatocellular Carcinoma 58 Cloretazine ® 58 www.ninds.nih.gov 58 hyaluronidase enzyme 58 pharmacogenomic translational research 58 Hepatocellular Carcinoma HCC 58 relapsing remitting MS RRMS 58 www.sigma 58 MVA MUC1 IL2 58 CARE HF 58 postapproval 58 BRILINTA 58 Patient Registry 58 RhuDex ® 58 Fx #A 58 retrospective cohort 58 Omnitarg 58 Bucindolol 58 Combination REOLYSIN R 58 PreGen Plus 58 CYT# QbG# 58 regorafenib 58 Anticalin ® 58 www.bdal.com 58 ENGAGE AF TIMI 58 Xelox 58 BARI 2D 58 Oral Fingolimod 58 Phase IIB 58 PDE# inhibitors 58 visit www.sanofi aventis.us 58 enzastaurin 58 Huntexil 58 cladribine tablets 58 tesmilifene 58 RE LY ® 58 Calcium Acetate 58 VESTASYNC 58 MedLine 58 NCDB 58 evaluating tivozanib 58 Phase IIa trials 58 TG MV 58 www.BMRN.com 58 www.targacept.com 58 HuMax TAC 58 Diamyd ® 58 Metabolic Endocrinology 58 www.iconplc.com 58 double blinded placebo 58 Cloretazine R 58 NSABP 58 ADVEXIN therapy 58 ConclusionThis 58 Pemetrexed 58 Diabetic Foot Ulcer 58 Prostate AdenoCarcinoma Treatment 58 toenail onychomycosis 58 call #.#.NEXAVAR #.#.#.# 58 ORAL Sync 58 phase IIa 58 teriflunomide 58 HORIZONS AMI trial 58 AFREZZA TM 58 journal Rheumatology 58 Ambrisentan 58 HDAC Inhibitor 58 Monoclonal antibody 58 ataluren 58 ONTARGET 58 abstracts summarizing 58 lorvotuzumab mertansine 58 Intervention Trial GAIT 58 Intervention Effectiveness 58 relapsing multiple sclerosis 58 meta regression 58 Initiates Phase 2b 58 LAB CGRP 58 preclinical pharmacokinetic 58 POSIDUR TM 58 www.amarincorp.com 58 DASISION 58 TEC #OL 58 ixabepilone 58 registrational Phase 58 Hodgkin lymphoma HL 58 eprodisate Fibrillex TM 58 Molecular Cancer 58 Hepsera adefovir dipivoxil 58 PRESEPT 58 www.maxygen.com 58 CAMMS# 58 oral rivaroxaban 58 pancreatic neuroendocrine tumors 58 multicenter randomized controlled 58 patientswith 58 www.whitepages.com 58 journal Hepatology 58 thalidomide Thalomid 58 assn.org 58 RESOLUTE clinical 58 Secondary efficacy endpoints 58 canakinumab 58 www.nfp.com 58 ibandronate 58 huN# DM1 58 BoNTA 58 elotuzumab 58 TNFerade TM 58 OVA1 ® 58 Phase Ib study 58 www.questcor.com 58 PARTNER Trial 58 Twinrix 58 Alzhemed TM 58 IMC #B 58 Teriflunomide 58 hoFH 58 multicenter prospective 58 Kevetrin ™ 58 TASKi3 58 Valopicitabine 58 ALN VSP Phase 58 CTAP# Capsules 58 ADVANCE PD 58 headache nasopharyngitis 58 Rheumatoid Arthritis RA 58 www.chemaphor.com 58 Nasdaq PPHM 58 Diabetic Nephropathy 58 EndoTAG TM -1 58 Hsp# Inhibitor 58 null responder 58 ACOMPLIA R 58 Sapacitabine 58 Initiates Phase II 58 Elagolix 58 Tigecycline 58 Phase III TRIST 58 SPRYCEL ® 58 ACCOMPLISH 58 www.cellgenesys.com 58 balsalazide tablet 57 CEQ# 57 gastrin analogue TT 57 ECTRIMS 57 bardoxolone methyl 57 www.anthera.com 57 http:/www.torreypinestherapeutics.com 57 BMC Musculoskeletal Disorders 57 www.baxa.com 57 PRECISE trial 57 http:/www.thrombogenics.com 57 Completes Dosing 57 www.bio rad.com 57 recurrent glioma 57 Initiate Clinical Trial 57 www.phtcorp.com 57 R rosiglitazone maleate 57 ATACAND 57 TransVax ™ 57 PSMA ADC 57 APPRAISE 57 Diabetologia 57 oral dnaJP1 57 preclinical efficacy 57 Initiates Enrollment 57 DNA methylation markers 57 haematological 57 http:/www.genta.com 57 Triapine 57 ExTRACT TIMI 57 Phase 2b Clinical Trial 57 TRO# 57 controlled multicenter 57 reslizumab 57 CELVAPAN H#N# 57 http:/www.JazzPharmaceuticals.com 57 REVIVE Diabetes 57 RhuDex R 57 recurrent glioblastoma multiforme 57 LHRH antagonists 57 multiple myeloma MM 57 Inflammatory Bowel Diseases 57 TÎ ² 4 57 relapsed refractory multiple myeloma 57 evaluating Actimmune 57 Cancer Genetic Markers 57 endometriosis ovarian cysts 57 www.codexis.com 57 CRLX# 57 www.nature.com 57 Fingolimod 57 Metametrix 57 AZILECT ® 57 novel therapeutic antibodies 57 efalizumab 57 variceal bleeding 57 Randomized Phase 57 ASSERT 57 NCIC CTG 57 Randomized Evaluation 57 www.givenimaging.com 57 preclinically 57 LHRH receptor positive 57 rALLy 57 Chronic lymphocytic leukemia 57 selective agonists 57 evaluating REVLIMID 57 Anturol TM 57 fusion enhancers 57 Zometa zoledronic acid 57 designated HVTN 57 Benign Prostatic Hyperplasia 57 cathepsin K inhibitor 57 ganaxolone 57 Dalbavancin 57 http:/www.ariad.com 57 cisplatin gemcitabine 57 inhaled AAT 57 PREVENT IV 57 EURIDIS 57 Akt inhibitor 57 eculizumab therapy 57 Femara letrozole 57 Degarelix 57 CLL8 57 ® pioglitazone HCl 57 Soft Tissue Sarcoma 57 RezularTM 57 UVIDEM 57 tipranavir 57 ongoing Phase 1b 57 www.durect.com 57 Xyrem ® 57 ZYBRESTAT TM 57 EGFR HER2 57 www.verichipcorp.com 57 Phase III multicenter 57 Antiviral Therapy 57 hypoparathyroidism 57 Systemic Sclerosis 57 EMBASE 57 Intervention Effectiveness CATIE 57 cardiac repolarization 57 prospective randomized placebo 57 Arzerra TM 57 dose escalation clinical 57 America HFSA 57 Ramelteon 57 Actilon 57 EVEREST II 57 Histological 57 SANVAR 57 www.vionpharm.com 57 www.adventrx.com 57 VeriStrat 57 www.isotechnika.com 57 PLCO 57 Alequel 57 Decitabine 57 AOD# [002] 57 www.ilgenetics.com 57 confirmatory clinical 57 phase Ib 57 Certican 57 Pulmonary Arterial Hypertension 57 rFSH 57 Human Mutation 57 Sunovion 57 prucalopride 57 pain palliation 57 randomized discontinuation trial 57 www.shire.com 57 Immunotherapeutic 57 endothelin antagonists 57 lintuzumab SGN 57 Glatiramer Acetate 57 OLYMPIA registry 57 rilonacept 57 ELACYT 57 ACZ# 57 smoldering multiple myeloma 57 oral ridaforolimus 57 phase IIb 57 ALTROPANE 57 Aurora Kinase 57 KRAS variant 57 http:/www.baxa.com 57 BUPHENYL R 57 http:/www#.best-in-class.com/br#.htm 57 Triolex 57 http:/www.reprosrx.com 57 pharmacokinetic PK study 57 CURRENT OASIS 7 57 Recombinant Human 57 IMPACT DCM 57 HQK 57 Rosetta Genomics microRNA 57 systemic juvenile idiopathic 57 Sycrest 57 IIa clinical 57 oral methylnaltrexone 57 ELND-#/AZD-# 57 Drug Pipeline 57 TLK# 57 Fabry Disease 57 opioid naive 57 GATTEX TM 57 VICTOR E1 57 BRAF inhibitor 57 Syllego system 57 Phase III psoriasis 57 basal bolus regimen 57 visit www.skincancer.org 57 IMiDs R 57 Vectibix panitumumab 57 prospective multicenter 57 http:/www.pharmacopeia.com 57 pregabalin Lyrica 57 K ras mutations 57 Completes Patient Enrollment 57 CCR5 antagonist 57 placebo controlled multicenter 57 Preclinical Models 57 www.advaxis.com 57 PROSTVAC VF 57 Stage IIIb 57 lipid lowering drugs 57 SCIB1 57 Rebif ® 57 BPS IC 57 DBMD 57 hypertension osteoarthritis 57 NO# [002] 57 non nucleoside inhibitor 57 www.diagnocure.com 57 Octreolin 57 metastatic GIST 57 www.caliperLS.com 57 USpella 57 intravesical infusion therapy 57 EORTC 57 ACTIVE W 57 www.sematech.org 57 Lucanix 57 Refractory Angina 57 www.achillion.com 57 deCODE AF TM 57 epoetin alpha 57 Wisconsin Sleep Cohort 57 www.annals.org 57 www.aidshealth.org 57 www.geovax.com 57 registrational 57 ACCORD Eye 57 recurrent malignant glioma 57 ATL# [001] 57 STK# gene 57 www.cambrex.com 57 huC# DM4 57 fidaxomicin Phase 57 receptor tyrosine kinase inhibitor 57 Chronic myeloid leukemia 57 polycythemia vera essential thrombocythemia 57 intradermal injections 57 Elvitegravir 57 antiarrhythmic drug 57 CLARITY study 57 pyridostigmine 57 CLARITY TIMI 57 neuropathologic 57 www.insmed.com 57 HPTN 57 Acthar Gel 57 Gastrointestinal Stromal Tumors 57 http:/www.staar.com 57 ritonavir boosted 57 AVAPRO 57 postmarketing adverse 57 Phase 2b Study 57 orally inhaled migraine 57 pertuzumab 57 candidates Dyloject TM 57 protein kinase inhibitors 57 journal Lancet Neurology 57 www.sciclone.com 57 oral salmon calcitonin 57 OPT CHF 56 Dupuytren Contracture 56 visit www.marrow.org 56 Vicriviroc 56 IPL# 56 VICTOR E3 56 Oglemilast 56 www.lonza.com 56 chronic idiopathic thrombocytopenic purpura 56 Phase 2b monotherapy 56 Catheter Associated 56 CVac 56 http:/www.idenix.com 56 Screening Trial DMIST 56 ILLUMINATE 56 Lp PLA 2 56 Randomised 56 sci.com 56 prelicensure 56 www.synchronica.com 56 please visit www.anci 56 PEG SN# 56 Azedra 56 LT NS# 56 vismodegib 56 Etanercept 56 AGHD 56 Contraindications 56 PCI ExTRACT TIMI 56 pan HDAC inhibitor 56 GOUT 56 randomized controlled trials RCTs 56 REVIVE TA 56 Vimpat R 56 Nonalcoholic fatty liver 56 www.oxigene.com 56 http:/www.orexigen.com 56 Tß4 56 collagen vascular 56 randomized multicenter trial 56 azilsartan medoxomil 56 www.helicosbio.com 56 HuLuc# 56 Val HeFT 56 Urocidin 56 chronic myeloid 56 visit www.#.com 56 Rigel R# 56 SORT OUT III 56 refractory metastatic 56 localized prostate 56 DCCR 56 retinal vein occlusion induced 56 Achieves Primary Endpoint 56 Advanced Renal Cell 56 ticagrelor Brilinta 56 evaluating satraplatin 56 antiplatelet medications 56 nucleotide analogue 56 fostamatinib 56 Clinical Trials Registry 56 terlipressin 56 Pafuramidine 56 http:/www.exonhit.com 56 metaanalysis 56 mutated K ras 56 ROCKET AF 56 www.resverlogix.com 56 thromboembolic disease 56 GATTEX ™ 56 Multiple Ascending Dose 56 EORTC NCI 56 noninvasive outpatient 56 Testosterone MDTS ® 56 Sprycel dasatinib 56 T1DM 56 Tyrosine Kinase Inhibitor 56 Tarceva TM 56 relapsed leukemia 56 MADIT II 56 HuMax 56 www.nexmed.com 56 specified primary endpoint 56 www.act 56 www.webmd.com 56 HIV HCV coinfected 56 Allovectin 7 56 Adventrx Pharmaceuticals Inc 56 Initiate Phase 56 pediatric acute lymphoblastic 56 thetreatment 56 GAMMAGARD 56 TransMID 56 glucokinase activator 56 Environ Health Perspect 56 MGd 56 Schizophrenia Treatment 56 Estrogen Receptor 56 tipifarnib 56 Phase IIa trial 56 www.solerainc.com 56 Tykerb lapatinib 56 CIPN 56 Randomized controlled 56 glatiramer 56 Patient Outcomes 56 Phase 2a Study 56 RELOVAIR ™ 56 www.sanofi aventis.com 56 iPrEx 56 buccal spray 56 Nasdaq ONXX today 56 Active Ulcerative Colitis 56 PrevOnco ™ 56 JAK inhibitor 56 www.jazzpharmaceuticals.com 56 Ozarelix 56 DOSAGE AND ADMINISTRATION 56 CINQUIL 56 oral PTH 56 RIO Lipids 56 IMPROVE HF 56 cardiovascular calcification 56 ON #.Na 56 Symadex 56 TRIST 56 Pharmacokinetics PK 56 mGluR2 NAM 56 Major Depressive Disorder MDD 56 alemtuzumab MS 56 MoxDuo TM IR 56 Pazopanib 56 Investigational Drug 56 investigational therapies 56 RECORD1 56 Marqibo TM 56 Initiate Phase II 56 Medidur TM FA 56 Initiates Clinical 56 www.marshalledwardsinc.com 56 Systemic Lupus Erythematosus 56 SUCCEED trial 56 AERx iDMS 56 www.BSDMedical.com 56 circulating endothelial cells 56 www.cerus.com 56 PD2i CA 56 Successfully Completes Phase 56 paclitaxel poliglumex 56 Golimumab 56 bepotastine besilate nasal spray 56 www.appharma.com 56 EEG abnormalities 56 metastatic CRC 56 multicenter randomized clinical 56 gp# protein [002] 56 TLR antagonist 56 generation URAT1 inhibitor 56 beta blockers ACE inhibitors 56 star.edu.sg 56 Mg Usa 56 www.macdonaldmines.com 56 visit www.nasdaq.com indexes 56 CIMZIA TM 56 randomized multicenter Phase III 56 Serdolect ® 56 Phase III Clinical Trial 56 www.nymox.com email info@nymox.com 56 www.pnas.org 56 Fibrillex TM 56 bioequivalency 56 Aeolus Pharmaceuticals Announces 56 orally administered inhibitor 56 BLA filing 56 novel oral anticoagulant 56 Genentech Rituxan 56 Vitaxin 56 NeuroStar TMS Therapy 56 LCP AtorFen 56 gefitinib Iressa 56 www.connectionnewspapers.com 56 DermaVir Patch 56 ECASS 56 visit www.LifeVantage.com 56 www.ibioinc.com 56 www.rodmanandrenshaw.com 56 Eli Lilly Cymbalta 56 overactive bladder syndrome 56 dyslipidaemia 56 www.acusphere.com 56 Multicenter AIDS 56 BEZ# 56 Angiolix 56 www.nih.gov 56 Reports Preclinical Data 56 Vascugel ® 56 www.cdc.gov nchs 56 Talabostat 56 MabThera rituximab 56 randomized controlled Phase 56 landmark ATHENA 56 PAOD 56 haematologic 56 longitudinal cohort study 56 www.regenerx.com 56 eCRF 56 Kahalalide F